Cantor Fitzgerald Estimates CATX FY2024 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Perspective Therapeutics in a note issued to investors on Wednesday, February 5th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of ($0.90) for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. Cantor Fitzgerald also issued estimates for Perspective Therapeutics' FY2025 earnings at ($1.09) EPS.

CATX has been the topic of several other reports. Royal Bank of Canada reissued an "outperform" rating and set a $16.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, January 14th. Bank of America lowered Perspective Therapeutics from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. UBS Group initiated coverage on Perspective Therapeutics in a research report on Thursday, October 24th. They set a "buy" rating and a $20.00 price objective on the stock. Wedbush reissued an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Friday, January 24th. Finally, Oppenheimer cut their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, November 22nd. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Perspective Therapeutics currently has an average rating of "Buy" and an average price target of $15.14.

Perspective Therapeutics Price Performance

Shares of CATX stock traded down $0.04 during mid-day trading on Friday, hitting $3.28. The stock had a trading volume of 289,332 shares, compared to its average volume of 992,966. Perspective Therapeutics has a 12-month low of $2.70 and a 12-month high of $19.05. The firm's 50-day moving average is $3.45 and its two-hundred day moving average is $9.10.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting analysts' consensus estimates of ($0.21). The firm had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%.

Insider Buying and Selling

In other news, CFO Jonathan Robert Hunt acquired 12,829 shares of Perspective Therapeutics stock in a transaction dated Monday, November 25th. The stock was purchased at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the completion of the purchase, the chief financial officer now directly owns 48,800 shares in the company, valued at $186,416. This trade represents a 35.66 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Heidi Henson bought 25,975 shares of the company's stock in a transaction that occurred on Wednesday, December 4th. The stock was purchased at an average price of $3.85 per share, for a total transaction of $100,003.75. Following the transaction, the director now owns 25,975 shares of the company's stock, valued at $100,003.75. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 67,570 shares of company stock worth $256,789 in the last three months. Corporate insiders own 3.52% of the company's stock.

Hedge Funds Weigh In On Perspective Therapeutics

Institutional investors have recently bought and sold shares of the business. FMR LLC increased its stake in shares of Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company's stock worth $73,489,000 after acquiring an additional 5,370,392 shares during the period. Nicholson Wealth Management Group LLC acquired a new stake in Perspective Therapeutics during the 3rd quarter worth about $21,390,000. State Street Corp raised its stake in shares of Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company's stock valued at $29,240,000 after buying an additional 1,192,812 shares during the last quarter. Hills Bank & Trust Co purchased a new position in shares of Perspective Therapeutics during the 3rd quarter valued at about $13,722,000. Finally, Janus Henderson Group PLC lifted its holdings in shares of Perspective Therapeutics by 8.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company's stock valued at $64,014,000 after buying an additional 355,685 shares during the period. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.